• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Anette Breindl

Articles by Anette Breindl

BioWorld MedTech’s Oncology Extra for April 21, 2020

April 21, 2020
By Mark McCarty and Anette Breindl
Keeping you up to date on recent developments in oncology, including: Targeted Interleukin-12 heats up cold tumors; Therapy allows immune system to ‘manganese’ up against cancer; Proton therapy less toxic than IMRT in new study; Technetium supplies struggling under distribution headaches.
Read More

BioWorld MedTech’s Cardiology Extra for April 20, 2020

April 20, 2020
By Liz Hollis and Anette Breindl
Keeping you up to date on recent developments in cardiology, including: Modeling the post-infarct heart; Researchers: Cancer immunotherapy poses threat to heart muscle; Lighting up the path for heart procedures.
Read More
Keith Ligon, chief of neuropathology, Brigham and Women's Hospital

For gliomas, hypermutated does not mean sensitive to checkpoint blockade

April 17, 2020
By Anette Breindl
The largest study to date on hypermutated gliomas has delivered new insights into their origin, as well as their response to several different treatments. Specifically, even though they are hypermutated, such tumors are unlikely to respond to PD-1 blockers.
Read More

BioWorld MedTech’s Neurology Extra for April 17, 2020

April 17, 2020
By Andrea Applegate and Anette Breindl
Keeping you up to date on recent developments in neurology, including: Gene variant may protect against Alzheimer's; Miniature microscope used to study neural circuit activity in nonhuman primate model; Dopamine has epigenetic role in addiction; Depression’s structural problem.
Read More
Structure of pyocin R2

Bench Press for April 17, 2020

April 17, 2020
By Anette Breindl
BioWorld looks at translational medicine, including: Engineering better bacterial backstabbers; Targeting bystander protein improves sepsis outcome; Long noncoding RNA has sex-specific role in depression; Targeted IL-12 heats up cold tumors; Fast route from fibroblasts to photoreceptors; Eating pro-inflammatory IgG helps prevent liver failure; Depression’s structural problem; Modeling the post-infarct heart; Interleukins rile each other up in reaction to implants; Complement links high BMI to dementia.
Read More
Keith Ligon, chief of neuropathology, Brigham and Women's Hospital

For gliomas, hypermutated does not mean sensitive to checkpoint blockade

April 15, 2020
By Anette Breindl
The largest study to date on hypermutated gliomas has delivered new insights into their origin, as well as their response to several different treatments. Specifically, even though they are hypermutated, such tumors are unlikely to respond to PD-1 blockers.
Read More
Microneedle array vaccine
Vaccines

The next pandemic: Speeding development and stretching supplies

April 14, 2020
By Anette Breindl
“Vaccines, obviously, are the ultimate solution for pandemics,” Rino Rappuoli told BioWorld. They have, he added, “already eliminated a lot of pandemic threats – smallpox, influenza, poliomyelitis.”
Read More
Natural killer cell
Drugs

The next pandemic: Firebreaks and host-directed therapies

April 14, 2020
By Anette Breindl
Specific therapies against a new disease take time to develop. But there are methods that can speed up that development.
Read More
1918-19 Spanish flu patient, paramedics, ambulance
Surveillance

The next pandemic: Death, taxes and zoonotic spillover

April 14, 2020
By Anette Breindl
“In any crisis, leaders have two equally important responsibilities: solve the immediate problem and keep it from happening again."
Read More

BioWorld MedTech’s Oncology Extra for April 14, 2020

April 14, 2020
By Mark McCarty and Anette Breindl
Keeping you up to date on recent developments in oncology, including: Medical societies ink guidelines for breast cancer care for pandemic; Multiple drivers explained; Study points to new genetic associations for osteosarcoma.
Read More
Previous 1 2 … 81 82 83 84 85 86 87 88 89 … 392 393 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 27, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 27, 2025.
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • Salvia Bioelectronics MySalvia implant

    Salvia raises $60M for neuromodulation migraine system

    BioWorld MedTech
    Salvia Bioelectronics BV raised $60 million in a series B financing round for its minimally invasive implantable neuromodulation device, Mysalvia therapy, which...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe